Bi 1994.

Methods	Randomisation: randomised, no further details. Allocation: procedure not described. Blinding: n.i., probably open. Duration: 4 weeks. Design: parallel. Location: n.i.. Setting: n.i..
Participants	Diagnosis: schizophrenia (Research Diagnostic Criteria RDC) and (CCMD‐2, Chinese classification of mental disorders). N = 37. Gender: 24 M, 26 F. Age: 18‐45 years. History: duration stable ‐ n.i., duration ill ‐ n.i., number of previous hospitalisations ‐ n.i., age at onset ‐ n.i., severity of illness ‐ n.i., baseline antipsychotic dose ‐ n.i..
Interventions	1. Haloperidol: fixed/flexible dose n.i., allowed dose range 5 to 100 mg/day, mean dose n.i.. N = 17. 2. Chlorpromazine: fixed/flexible dose n.i., allowed dose range 50 to 500 mg/day, mean dose n.i.. N = 20. Other medication: n.i..
Outcomes	Response to treatment: BPRS (no clear definition). Leaving the study early. Mental state: BPRS. Global state: CGI. Adverse effects: at least one movement disorder, average score change in EPS.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further details.
Allocation concealment (selection bias)	Unclear risk	Procedure not described.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not indicated, probably open.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Not indicated, probably open.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement about incomplete outcome data.
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgment about selective reporting.
Other bias	Low risk	No clear other bias.